PT  - JOURNAL ARTICLE
AU  - Christian Skalafouris
AU  - Caroline Samer
AU  - Jerome Stirnemann
AU  - Olivier Grosgurin
AU  - François Eggimann
AU  - Damien Grauser
AU  - Jean-Luc Reny
AU  - Pascal Bonnabry
AU  - Bertrand Guignard
TI  - Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19
AID  - 10.1136/ejhpharm-2020-002667
DP  - 2023 Mar 01
TA  - European Journal of Hospital Pharmacy
PG  - 113--116
VI  - 30
IP  - 2
4099  - http://ejhp.bmj.com/content/30/2/113.short
4100  - http://ejhp.bmj.com/content/30/2/113.full
SO  - Eur J Hosp Pharm2023 Mar 01; 30
AB  - During Switzerland’s first wave of COVID-19, clinical pharmacy activities during medical rounds in Geneva University Hospitals were replaced by targeted remote interventions. We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines. Of 416 patients receiving LPVr and/or HCQ, 182 alerts were triggered for 164 (39.4%) patients. The main associated risk factors of ADEs were drug–drug interactions, QTc interval prolongation, electrolyte disorder and inadequate LPVr dosage. Therapeutic optimisation recommended by a pharmacist or proposals for additional monitoring were accepted in 80% (n=36) of cases. Combined with pharmacist contextualisation to the clinical context, PharmaCheck made it possible to successfully adapt clinical pharmacist activities by switching from a global to a targeted analysis mode in an emergency context.All data relevant to the study are included in the article or uploaded as supplementary information.